Share

May 15, 2012; 78 (20) Articles

Prevalence and comorbidity of nocturnal wandering in the US adult general population

M.M. Ohayon, M.W. Mahowald, Y. Dauvilliers, A.D. Krystal, D. Léger
First published May 14, 2012, DOI: https://doi.org/10.1212/WNL.0b013e3182563be5
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
660

Share

Article Information

vol. 78 no. 20 1583-1589
DOI: 
https://doi.org/10.1212/WNL.0b013e3182563be5
PubMed: 
22585435
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received October 13, 2011
  • Accepted January 17, 2012
  • First Published May 14, 2012.
Copyright & Usage: 
Copyright © 2012 by AAN Enterprises, Inc.

Author Disclosures

    1. M.M. Ohayon, MD, DSc, PhD,
    2. M.W. Mahowald, MD,
    3. Y. Dauvilliers, MD, PhD,
    4. A.D. Krystal, MD, MS and
    5. D. Léger, MD, PhD
  1. M.M. Ohayon, MD, DSc, PhD,
    2. Scientific Advisory Boards:

    1. Sanofi-Aventis, scientific advisory board Pfizer Inc,scientific advisory board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Sleep, editorial advisory board, 1998-present; Sleep Medicine, editorial advisory board, 2000- present; Journal of Psychiatry Research, Assistant Editor, 2006-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. Panelist at a FDA-PERI co-sponsored workshop on The Safety and Efficacy of Hypnotic Drugs, 2011

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Grant from Neurocrines Biosciences for educational activities 2) Research gift from Jazz Pharmaceuticals

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. M.W. Mahowald, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial advisory board: Sleep and Sleep Medicine (resigned from both one year ago)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Y. Dauvilliers, MD, PhD,
    4. Scientific Advisory Boards:

    1. UCB; Sanofi-Aventis; Cephalon; Bioprojet, and; Novartis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. UCB; Sanofi-Aventis; Cephalon; Bioprojet, and; Novartis Speakers’ Bureaus:; UCB; Sanofi-Aventis; Cephalon; Bioprojet, and; Novartis

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. A.D. Krystal, MD, MS and
    5. Scientific Advisory Boards:

    1. Abbott, 2) Cephalon; Eisai; Eli Lilly; GlaxoSmithKline; Jazz; Merck; Neurocrine; Novartis; Phillips-Respironics; Sanofi-Aventis; Sunovion/Sepracor; Somaxon; Transcept; Kingsdown Inc.; Actelion

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Somaxon; Sunovion; Cephalon

    Editorial Boards:

    1. SLEEP, Associate Editor; Biological Psychiatry, Editorial Board; Mind and Brain, Editorial Board; SRP Journal of URology, Editorial Board; Current Psychiatry Reviews, Editorial Board; Journal of ECT and Related Therapies, Editorial Board; Stanford Journal of Sleep Epidemiology, Editorial Board

    Patents:

    1. Use of near-infrared optical imaging to optimize the dosing of transcranial magnetic stimulation.

    Publishing Royalties:

    1. Clinical Manual of Electroconvulsive Therapy; American Psychiatric Publishing Inc. 2010

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Abbott; AstraZeneca; Cephalon; Eisai; Eli Lilly; GlaxoSmithKline; Jazz; Johnson and Johnson; Merck; Neurocrine; Novartis; Pfizer; Phillips-Respironics; Roche; Sanofi-Aventis; Somnus; Sunovion/Sepracor; Somaxon; Takeda; Transcept; Kingsdown Inc.

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Sanofi-Aventis; Cephalon; GlaxoSmithKline; Merck; Neurocrine; Pfizer; Sunovion/Sepracor; Somaxon; Takeda; Transcept; Phillips-Respironics; Neurogen; Evotec; Astellas; Abbott; Neuronetics

    Research Support, Government Entities:

    1. NIH; U01MHAR052155 (PI-Krystal) 2009-2011; NHLBI R01HL096492 (PI-Krystal) 2009-2013; NIAMS R01 AR052368 (PI: Edinger) 2006-2011; NIMH R01 MH078961-01A2 (PI: Edinger) 2008-2013; NIDDK R01 DK087717 (PI: Krystal) 2010-2013; NINR R21 NR010539 (PI: Krystal) 2007-2010; 5U01 AR 052186 (PI:Weinfurt) 2004-2009; R01 MH067057 (PI: Edinger) 2004-2009; NIMH R01 MH076856 (PI: Carney) 2008–2009; NIMH R01 MH091053-01A1 (PI: Edinger)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Attentiv

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Astra-Zeneca: Expert witness 2009-present

  5. D. Léger, MD, PhD
    6. Scientific Advisory Boards:

    1. Sanofi-Aventis; Lundbeck; Actelion; GSK; Lilly; Pfizer; Merck; Philips Respironics; Vanda; Bioprojets; APL; Zyken; Air Liquide international

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Sleep Research; Medecine du Sommeil; Sleep Medecine Review

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Sanofi-Aventis; Lundbeck; Actelion; GSK; Lilly; Pfizer; Merck; Philips Respironics; Vanda; Bioprojets; APL; Zyken; Air Liquide International

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Sanofi-Aventis; Lundbeck; Actelion; GSK; Lilly; Pfizer; Merck; Philips Respironics; Vanda; Bioprojets; APL; Zyken; Air Liquide International

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Stanford Sleep Epidemiology Research Center (M.M.O.), School of Medicine, Stanford University, Stanford, CA; Minnesota Regional Sleep Disorders Center (M.W.M.), Department of Neurology, Hennepin County Medical Center, The University of Minnesota Medical School, Minneapolis; Centre de Référence Nationale Maladie Rare–Narcolepsie et Hypersomnie Idiopathique (Y.D.), Service de Neurologie, Hôpital Gui-de-Chauliac, Inserm U1061, Montpellier, France; Duke University School of Medicine (A.D.K.), Durham, NC; and Université Paris Descartes (D.L.), APHP, Hôtel-Dieu de Paris, Centre du Sommeil et de la Vigilance, Paris, France.
  1. Correspondence & reprint requests to Dr. Ohayon: mohayon{at}stanford.edu
View Abstract

Article usage

Article usage: May 2012 to October 2023

AbstractFullPdfSource
May 201225657252Highwire
Jun 20124162513Highwire
Jul 20123081414Highwire
Aug 20121761118Highwire
Sep 201215985Highwire
Oct 20121691211Highwire
Nov 2012181117Highwire
Dec 201211794Highwire
Jan 20139353Highwire
Feb 201313023Highwire
Mar 201313455Highwire
Apr 201313302Highwire
May 20139933Highwire
Jun 20139523Highwire
Jul 201312642Highwire
Aug 20139622Highwire
Sep 201311630Highwire
Oct 201313248Highwire
Nov 201312186Highwire
Dec 201310555Highwire
Jan 201410961Highwire
Jan 20142136pmc
Feb 20149252Highwire
Mar 2014121126Highwire
Apr 201475167Highwire
May 201411086Highwire
Jun 20146622Highwire
Jul 20146510Highwire
Aug 20148901Highwire
Sep 20149922Highwire
Oct 201411702Highwire
Nov 201414311Highwire
Dec 201410700Highwire
Jan 20157600Highwire
Jan 20150116pmc
Feb 201510001Highwire
Feb 201502018pmc
Mar 201514011Highwire
Mar 20150147pmc
Apr 20156800Highwire
Apr 20150144pmc
May 20156300Highwire
May 20150886pmc
Jun 20156911Highwire
Jun 201502311pmc
Jul 20157801Highwire
Jul 20150166pmc
Aug 20157610Highwire
Aug 20150128pmc
Sep 20159600Highwire
Sep 20150455pmc
Oct 20159531Highwire
Oct 20150104pmc
Nov 20155922Highwire
Nov 201503314pmc
Dec 20157500Highwire
Dec 20150244pmc
Jan 201616100Highwire
Jan 20160150pmc
Feb 20165423Highwire
Feb 20160114pmc
Mar 20168900Highwire
Mar 20160155pmc
Apr 201612612Highwire
Apr 20160179pmc
May 20167213Highwire
May 20160163pmc
Jun 20168922Highwire
Jun 2016092pmc
Jul 201612300Highwire
Jul 20160637pmc
Aug 201610200Highwire
Aug 20160225pmc
Sep 201613200Highwire
Sep 20160185pmc
Oct 20167304Highwire
Oct 20160135pmc
Nov 20168714Highwire
Nov 20160248pmc
Dec 20164900Highwire
Dec 20160215pmc
Jan 20176400Highwire
Jan 20170166pmc
Feb 20176402Highwire
Feb 20170158pmc
Mar 20176600Highwire
Mar 20170214pmc
Apr 20175900Highwire
Apr 201771920pmc
May 20174901Highwire
May 201711214pmc
Jun 20174001Highwire
Jun 201721213pmc
Jul 201734101Highwire
Jul 201731818pmc
Aug 20174821Highwire
Aug 201711415pmc
Sep 20175012Highwire
Sep 201731212pmc
Oct 20174811Highwire
Oct 201743850pmc
Nov 20177300Highwire
Nov 201731413pmc
Dec 20174300Highwire
Jan 20186520Highwire
Feb 201885101Highwire
Mar 20187200Highwire
Apr 20185110Highwire
Apr 2018102125pmc
May 201819331Highwire
Jun 20189520Highwire
Jun 201851514pmc
Jul 20187700Highwire
Aug 20184900Highwire
Aug 201821213pmc
Sep 20184000Highwire
Oct 20188111Highwire
Nov 20187601Highwire
Dec 20186100Highwire
Jan 20196162Highwire
Feb 20198225Highwire
Mar 20196311Highwire
Apr 20197611Highwire
May 20197000Highwire
Jun 20195500Highwire
Jul 20194600Highwire
Aug 20194200Highwire
Sep 20196112Highwire
Oct 20196300Highwire
Nov 20196000Highwire
Dec 20193901Highwire
Jan 20205911Highwire
Feb 20207422Highwire
Mar 20205900Highwire
Apr 20208610Highwire
May 20208610Highwire
Jun 20207322Highwire
Jul 20206954Highwire
Aug 20206300Highwire
Sep 20208000Highwire
Oct 20207800Highwire
Nov 202010332Highwire
Dec 20206610Highwire
Jan 20215910Highwire
Feb 20214920Highwire
Mar 20216001Highwire
Apr 20215500Highwire
May 20218011Highwire
Jun 20214421Highwire
Jul 20219020Highwire
Aug 20218910Highwire
Sep 20216410Highwire
Oct 20215510Highwire
Nov 202111100Highwire
Dec 20218111Highwire
Jan 20226600Highwire
Feb 20226100Highwire
Mar 20228921Highwire
Apr 20225000Highwire
May 20227722Highwire
Jun 20226112Highwire
Jul 20226401Highwire
Aug 20228211Highwire
Sep 20224110Highwire
Oct 20224311Highwire
Nov 20228101Highwire
Dec 20227100Highwire
Jan 202310464Highwire
Feb 20235000Highwire
Mar 20238622Highwire
Apr 20236021Highwire
May 20233900Highwire
Jun 20233900Highwire
Jul 20234520Highwire
Aug 20233410Highwire
Sep 202322921Highwire
Oct 202312500Highwire

Letters: Rapid online correspondence

Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

More Online

CME Course

Topics Discussed

Alert Me

Recommended articles